View Issue Details

IDProjectCategoryView StatusLast Update
0029526MBM DemoPerformancepublic2022-07-13 23:34
Reporterguest Assigned To 
PrioritynormalSeverityminorReproducibilityhave not tried
Status newResolutionopen 
PlatformTZNlIePqLNHZOSlcClNZebCCADnxeV 
Summary0029526: We've got a joint account [url=https://www.qnez.net/naproxeno-sdico-precio-colombia-rvyy]naproxen 500 1a pharma erfahrungen[/url
DescriptionWe've got a joint account [url=https://www.qnez.net/naproxeno-sdico-precio-colombia-rvyy]naproxen 500 1a pharma erfahrungen[/url] Credit Suisse and Numis Securities acted as jointbookrunners on the offering, while Canaccord Genuity was co-leadmanager. The advisors will receive fees of 2 percent of theoffer size, plus a possible discretionary fee of 1 percent. ($1=0.6226 British pounds) (Additional reporting by Tom Bill; Editing by Greg Mahlich andDavid Holmes)
 
Steps To ReproduceWe've got a joint account [url=https://www.qnez.net/naproxeno-sdico-precio-colombia-rvyy]naproxen 500 1a pharma erfahrungen[/url] Credit Suisse and Numis Securities acted as jointbookrunners on the offering, while Canaccord Genuity was co-leadmanager. The advisors will receive fees of 2 percent of theoffer size, plus a possible discretionary fee of 1 percent. ($1=0.6226 British pounds) (Additional reporting by Tom Bill; Editing by Greg Mahlich andDavid Holmes)
 
Additional InformationWe've got a joint account [url=https://www.qnez.net/naproxeno-sdico-precio-colombia-rvyy]naproxen 500 1a pharma erfahrungen[/url] Credit Suisse and Numis Securities acted as jointbookrunners on the offering, while Canaccord Genuity was co-leadmanager. The advisors will receive fees of 2 percent of theoffer size, plus a possible discretionary fee of 1 percent. ($1=0.6226 British pounds) (Additional reporting by Tom Bill; Editing by Greg Mahlich andDavid Holmes)
 
TagsNo tags attached.
Attach Tags